By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

A key U.S. federal vaccine advisory panel has dropped a push against COVID mRNA vaccines, the Washington Post reported on Wednesday, citing two people familiar with the matter.

With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the ...

Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with mRNA ...

Moderna Inc.’s settlement to end a lawsuit over technology used in its Covid-19 vaccine caps its potential exposure at $2.25 ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be ...

Moderna said it met with the FDA on Tuesday to discuss the vaccine and afterward, the U.S. regulator accepted a revised ...

The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for the upcoming influenza season.

Europe's medicines regulator recommended approval for Moderna's COVID and flu combination vaccine on Friday, putting it on track to become the first single shot to ...

The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.